Pharma & Bio
Technology
The COVID-19 Boom Is Over… What Happened to the Korean Diagnostic Kits That Survived in the U.S.?
The U.S. will end the Emergency Use Authorization (EUA) system for diagnostic kits—which was temporarily permitted during the COVID-19 pandemic—at the end of this year. Going forward, the U.S. COVID-1…
Manufacturing
"Driven by PDRN, a New Growth Engine Derived from Ultra-Nano Probiotics, the Company Aims to Double Sales This Year and Return to Profit Next Year" [In-Depth Look at AccuGen ③]
AccuGen is accelerating its expansion into new bio-material businesses, including cosmetic and health functional food ingredients based on polydeoxyribonucleotide (PDRN) derived from lactic acid bacte…
Manufacturing
"Strengths in One-Stop Comprehensive Microbial Services, from AI Analysis to the Development, Production, and Delivery of Consumables" [In-Depth Look at AccuGen ②]
AccuGen is the only company in Korea to offer a one-stop comprehensive service that encompasses microbial analysis as well as the development, production, and delivery of consumables. AccuGen also hol…
Manufacturing
"Leaping from Genetic Testing and Medical Device Consumables to a Natural Microbial Materials Company" [In-Depth Look at AccuGen ①]
"We will transform AccuGen from a company specializing in genetic sample collection tubes and kits, as well as next-generation sequencing (NGS) microbiome testing, into a leading provider of natural m…
Business·Industry
A Look at Precedents in K-Bio That Claimed 'Half a Success'… Will Kolon TissueGene, Inc.’s 'TG-C' Be Different?
Jeon Seung-ho, co-CEO of Kolon TissueGene, Inc., held a press conference in Gangseo-gu, Seoul, on the 21st to announce the results of the U.S. Phase 3 clinical trial for “TG-C,” a cell-gene therapy fo…
Manufacturing
"From Product Introduction to Joint Venture Establishment"... HANDOK Inc. Sees Full Effect of Its Dual-Pronged Strategy for Cancer and Rare Diseases
Mid-sized pharmaceutical company HANDOK Inc.(002390)is continuing its trend of improved performance, driven by its dual focus on anticancer drugs and treatments for rare diseases. HANDOK Inc. has trad…
Lifestyle
Merck Sets Its Sights on Injenia’s New Eye Drug ‘IGT-427’... Outperforming Eylea and Bavisimo
Ingenia Therapeutics (Ingenia), a developer of treatments for microvascular diseases that has begun the public offering process for a KOSDAQ listing, has declared a paradigm shift in the age-related m…
Technology
KOSDAQ Biotech Rally...Alteogen Soars on European Patent Win [K-bio Pulse]
On July 23, the domestic stock market surged as expectations for artificial intelligence (AI) investments combined with strong momentum in healthcare and biotechnology stocks. The tech-heavy KOSDAQ ma…
Technology
[Bio Spotlight] Alteogen Inc. Soars After Shaking Off Patent Shackles… SAM CHUN DANG PHARM CO. LTD Warns Against 'FDA Mirage'
On the 23rd, the domestic stock market surged across the board, driven by expectations of expanded investment in artificial intelligence (AI) and a rally in biotech stocks. In particular, the KOSDAQ m…
Lifestyle
[Blue Ocean Veterinary Medical Devices] ④ Precision Biosensor Inc. on the Verge of Reaching 10 Billion Won in Veterinary Diagnostics Sales
As medical technology advances, the treatment of human diseases is evolving toward “personalized” and “precision medicine.” Consequently, demand for personalized treatment and precision medicine is no…